Small Pharma Analyst
Growth, long/short equity, biotech, healthcare

Protalix Biotherapeutics - A Compelling Buy Due To Validation Of Oral Protein Delivery Technology

On Feb 12, 2014, Protalix released the highly anticipated Phase I clinical data on its oral drug candidate for Gaucher's disease, PLX-112. Phase I studies were completed in 4Q2013 and are being presented at the Lysosomal Disease conference in San Diego on Feb 12. Nearly all therapeutic proteins are delivered via injection since the proteins are not stable in the highly acidic stomach. Using their proprietary plant-based technology, Protalix has developed an oral formulation that protects proteins in their journey through stomach and then are released in the milder pH conditions of the intestine by digestive enzymes secreted by the pancreas. PRX-112 is their first oral therapy to reach Phase I and demonstrating oral bioavailability in humans is a very...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details